ABT102 is a potent antagonist of the TRPV1 receptor, which plays a key role in the transmission of pain signals, particularly those associated with heat and inflammation. It has been investigated primarily for its potential in managing chronic pain conditions such as osteoarthritis and neuropathic pain. By blocking the TRPV1 receptor, ABT102 reduces the perception of pain without the side effects commonly associated with opioids or NSAIDs. It showed promise in clinical trials for providing analgesic effects, especially in patients who do not respond well to conventional pain therapies. However, development was discontinued due to safety concerns, including hyperthermia (elevated body temperature), which was observed in some trial participants. Despite this, ABT102 remains a valuable compound for studying TRPV1 receptor function and pain modulation pathways.